Table 3.

Variables associated with delayed times to transplant

VariableGroupIndication to consult >90 d, N, %P valueConsult to transplant >120 d, N, %P valueCR to transplant >90 d, N, %P valueIndication to transplant >180 d, N, %P value
Age, y ≤56 21/160, 13 0.87 32/160, 20 0.3 55/160, 34 0.59 34/160,21 .3 
 >56 22/153, 14  39/153, 25  58/153, 38  41/153,27  
Sex Male 18/163, 11 0.2 42/163, 29 0.2 64/163, 39 0.27 37/163,23 .68 
 Female 25/150, 17  29/150, 19  49/150, 33  38/150,25  
Ancestry†  European 21/214, 10 0.005∗  40/214, 19 0.019∗  66/214, 31 0.006∗  42/214,20 .012∗  
 Non-European 22/99, 22  31/99, 31  47/99, 47  33/99, 33  
HCT-CI 0-2 22/183, 12 0.38 38/183, 21 0.41 63/183, 34 0.5 38/183, 21 .15 
 3+ 21/130, 16  33/130, 25  50/130, 38  37/130, 28  
Graft source HLA-identical sibling 5/67, 7 0.11 8/67, 12 <0.001∗  17/67, 25 0.024∗  10/67, 15 .004∗  
 8/8 URD 20/149, 13  36/149, 24  62/149, 42  36/149, 24  
 CB 11/69, 16  11/69, 16  19/69, 28  15/69, 22  
 Haploidentical 3/17, 18  10/17, 59  9/17, 53  10/17, 59  
 mmURD 4/11, 36  6/11, 55  6/11, 55  4/11, 36  
Referral type Internal 17/199, 9 <0.001∗  56/199, 28 0.004∗  59/199, 30 0.003∗  47/199, 24 .9 
 External 26/114, 23  15/114, 13  54/114, 47  28/114, 25  
Period Prepandemic 32/260, 12 0.16 59/260, 19 >0.9 92/260, 35 0.7 63/260, 24 .9 
 Pandemic 11/53, 21  12/53, 23  21/53, 40  12/53, 23  
VariableGroupIndication to consult >90 d, N, %P valueConsult to transplant >120 d, N, %P valueCR to transplant >90 d, N, %P valueIndication to transplant >180 d, N, %P value
Age, y ≤56 21/160, 13 0.87 32/160, 20 0.3 55/160, 34 0.59 34/160,21 .3 
 >56 22/153, 14  39/153, 25  58/153, 38  41/153,27  
Sex Male 18/163, 11 0.2 42/163, 29 0.2 64/163, 39 0.27 37/163,23 .68 
 Female 25/150, 17  29/150, 19  49/150, 33  38/150,25  
Ancestry†  European 21/214, 10 0.005∗  40/214, 19 0.019∗  66/214, 31 0.006∗  42/214,20 .012∗  
 Non-European 22/99, 22  31/99, 31  47/99, 47  33/99, 33  
HCT-CI 0-2 22/183, 12 0.38 38/183, 21 0.41 63/183, 34 0.5 38/183, 21 .15 
 3+ 21/130, 16  33/130, 25  50/130, 38  37/130, 28  
Graft source HLA-identical sibling 5/67, 7 0.11 8/67, 12 <0.001∗  17/67, 25 0.024∗  10/67, 15 .004∗  
 8/8 URD 20/149, 13  36/149, 24  62/149, 42  36/149, 24  
 CB 11/69, 16  11/69, 16  19/69, 28  15/69, 22  
 Haploidentical 3/17, 18  10/17, 59  9/17, 53  10/17, 59  
 mmURD 4/11, 36  6/11, 55  6/11, 55  4/11, 36  
Referral type Internal 17/199, 9 <0.001∗  56/199, 28 0.004∗  59/199, 30 0.003∗  47/199, 24 .9 
 External 26/114, 23  15/114, 13  54/114, 47  28/114, 25  
Period Prepandemic 32/260, 12 0.16 59/260, 19 >0.9 92/260, 35 0.7 63/260, 24 .9 
 Pandemic 11/53, 21  12/53, 23  21/53, 40  12/53, 23  
∗

P values denote significant differences.

†

Time from transplant indication to transplant was >180 days in 10 of 28 (36%) White Hispanic, 9 of 23 (36%) African, and 5 of 28 (18%) Asian-ancestry patients.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal